Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
J Antibiot (Tokyo) ; 56(6): 513-9, 2003 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-12931859

RESUMO

A novel inhibitor of STAT6 activation, named as TMC-264 (1), was discovered from the fermentation broth of Phoma sp. TC 1674. Based on spectroscopic analyses, TMC-264 was found to be a novel tricyclic polyketide with chloro-1H-dibenzo[b,d]pyran-4,6-dione. TMC-264 suppressed expression of IL-4 driven luciferase and germline Cepsilon mRNA with IC50 values of 0.3 microM and 0.4 microM, respectively. TMC-264 exhibited a potent inhibitory activity against tyrosine phosphorylation of STAT6 with an IC50 value of 1.6 microM, whereas TMC-264 weakly inhibited tyrosine phosphorylation of STAT5 with an IC50 value of 16 microM, but did not inhibit the phosphorylation of STAT1 up to 40 microM. TMC-264 blocked formation of the complexes between phosphorylated STAT6 and STAT6 oligonucleotides in a dose dependent manner, while TMC-264 did not affect the formation of phosphorylated STAT1/STAT1 oligonucleotides complexes. These results suggested that TMC-264 selectively inhibited IL-4 signaling by interfering both of phosphorylation of STAT6 and binding of the phosphorylated STAT6 to the recognition sequence.


Assuntos
Compostos Heterocíclicos com 3 Anéis/farmacologia , Transativadores/antagonistas & inibidores , Cromatografia Líquida de Alta Pressão , Interações Medicamentosas , Fermentação , Células HeLa , Compostos Heterocíclicos com 3 Anéis/isolamento & purificação , Humanos , Interleucina-4/farmacologia , Fosforilação/efeitos dos fármacos , Fator de Transcrição STAT6 , Transdução de Sinais/efeitos dos fármacos
2.
Org Lett ; 5(7): 1083-5, 2003 Apr 03.
Artigo em Inglês | MEDLINE | ID: mdl-12659579

RESUMO

[structure: see text] TMC-264 (1), a novel tricyclic heptaketide with a unique chloro-1H-dibenzo[b,d]pyran-4,6-dione skeleton, was discovered from the fungus Phoma sp. TC 1674. The structure was elucidated on the basis of NMR analyses of normal abundance and biosynthetically (13)C-enriched TMC-264. TMC-264 showed potent inhibitory activity against tyrosine phosphorylation of STAT6.


Assuntos
Fungos/química , Compostos Heterocíclicos com 3 Anéis/química , Compostos Heterocíclicos com 3 Anéis/isolamento & purificação , Fungos/classificação , Compostos Heterocíclicos com 3 Anéis/farmacologia , Espectroscopia de Ressonância Magnética , Estrutura Molecular , Fosforilação/efeitos dos fármacos , Fosfotirosina/metabolismo , Fator de Transcrição STAT6 , Transativadores/metabolismo
3.
J Antibiot (Tokyo) ; 55(8): 685-92, 2002 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-12374380

RESUMO

New inhibitors of IL-4 signal transduction, designated as TMC-256A1 and C1, were discovered together with TMC-256B1, a previously known dihydronaphthopyrone, from the fermentation broth of Aspergillus niger var niger TC 1629 by using an IL-4 driven reporter gene assay. Based on spectroscopic analyses, TMC-256A1 and C1 were found to be new members of the naphthopyrone antibiotics. TMC-256A1, B1 and C1 inhibited the IL-4 driven luciferase activity with IC50 values of 25 microM, 30 microM and 1.7 microM, respectively in this assay system. Furthermore, these compounds inhibited the expression of germline C epsilon mRNA with IC50 values of 6.6 microM , 34 microM and 0.31 microM, respectively.


Assuntos
Antibacterianos/farmacologia , Aspergillus niger/metabolismo , Cromonas/metabolismo , Interleucina-4/antagonistas & inibidores , Naftalenos/farmacologia , Pironas/farmacologia , Transdução de Sinais/efeitos dos fármacos , Antibacterianos/química , Antibacterianos/metabolismo , Aspergillus niger/classificação , Linfócitos B/imunologia , Cromonas/química , Cromonas/farmacologia , Células HeLa , Humanos , Imunoglobulina E/metabolismo , Interferon gama/farmacologia , Interleucina-4/farmacologia , Luciferases/genética , Luciferases/metabolismo , Ativação Linfocitária , Espectroscopia de Ressonância Magnética , Naftalenos/química , Naftalenos/metabolismo , Pironas/química , Pironas/metabolismo , RNA Mensageiro/efeitos dos fármacos , RNA Mensageiro/metabolismo , Transfecção , Células Tumorais Cultivadas
4.
Cancer Lett ; 185(2): 173-9, 2002 Nov 28.
Artigo em Inglês | MEDLINE | ID: mdl-12169391

RESUMO

Here we report on the anti-tumor effects of five interferon (IFN)-alpha subtypes, alpha1, alpha2, alpha5, alpha8, and alpha10 in chronic myelogenous leukaemia (CML)-derived cell lines. All of the CML cells can respond to IFN-alpha although the anti-tumor effects of IFN-alpha depend on the target cell and on the type of IFN-alpha subtype used. Proliferation assays showed that IFN-alpha8 was substantially more effective than the other four IFN-alpha subtypes. IFN-alpha8 was the most potent at upregulating immunomodulatory molecule expression while IFN-alpha1 was least potent. These data indicate in vitro distinctions between IFN-alpha subtypes that should be appreciated more in the clinic.


Assuntos
Antineoplásicos/farmacologia , Fatores Imunológicos/farmacologia , Interferon-alfa/farmacologia , Leucemia Mielogênica Crônica BCR-ABL Positiva/patologia , Apoptose/efeitos dos fármacos , Divisão Celular/efeitos dos fármacos , Proteína Ligante Fas , Regulação Leucêmica da Expressão Gênica/efeitos dos fármacos , Genes MHC Classe I , Antígenos HLA/biossíntese , Humanos , Interferon Tipo I/farmacologia , Interferon alfa-2 , Interferon-alfa/classificação , Interferons/farmacologia , Glicoproteínas de Membrana/biossíntese , Glicoproteínas de Membrana/genética , Proteínas de Neoplasias/biossíntese , Proteínas de Neoplasias/genética , Proteínas Recombinantes , Células Tumorais Cultivadas/efeitos dos fármacos , Células Tumorais Cultivadas/metabolismo , Células U937/efeitos dos fármacos , Células U937/metabolismo , Receptor fas/biossíntese , Receptor fas/genética
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...